SMi has assembled an unparalleled team including Dan Von Hoff and Richard Love (founders of ILEX Oncology). SMi's founders, management and scientists have world-class reputations and experience in all aspects of translational drug development.

The unique relationships and credibility maintained by the Founders provide SMi unique access to large and small companies and to academic research groups as sources of product candidates which SMi believes can be made “better” by application of its “omics” approach.